Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21149889 | 0.92 | EPHX2 (0.42) | CNR2 | |
| SCHEMBL14402703 | 0.87 | TSHR (0.48) | TSHRL3MBTL1TDP1ALDH1A1CYP3A4 | |
| SCHEMBL10081323 | 0.87 | L3MBTL1 (0.54) | TSHRL3MBTL1TDP1 | |
| SCHEMBL4552958 | 0.84 | TSHR (0.45) | CETPCSNK1ETSHRCNR2 | |
| SCHEMBL28515540 | 0.84 | TSHR (0.45) | TSHRL3MBTL1TDP1ALDH1A1CYP3A4 | |
| SCHEMBL18606773 | 0.84 | TSHR (0.45) | CETPCSNK1ETSHRCNR2 | |
| SCHEMBL31362225 | 0.83 | CSNK1E (0.49) | CETPCSNK1ETSHRL3MBTL1TDP1 | |
| SCHEMBL23533573 | 0.83 | CSNK1E (0.49) | CETPCSNK1ETSHRL3MBTL1TDP1 | |
| SCHEMBL28788533 | 0.83 | CSNK1E (0.49) | CETPCSNK1ETSHRL3MBTL1TDP1 | |
| SCHEMBL26163484 | 0.83 | CSNK1E (0.49) | CETPCSNK1ETSHRL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | HCCS, CCL11, BCAT1 | CETP 1183/4885CSNK1E 1003/4885TSHR 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.